11 / 25
SUPERVIVENCIA GLOBAL
Motzer RJ, et al.
Lancet Oncol.
2015;16:1473-82
Lenvatinib/everolimus
vs
everolimus
HR=0.51 (95% CI, 0.30–0.88); P=0.024
Lenvatinib
vs
everolimus
HR=0.68 (95% CI, 0.41–1.14); P=0.12
Median OS, months
Lenvatinib/everolimus
25.5 (95% CI, 16.4–NE)
Lenvatinib
19.1 (95% CI, 13.6–26.2)
Everolimus
15.4 (95% CI, 11.8–19.6)
6
4
2
14
7
8
21
16
14
29
26
20
35
31
27
38
37
30
44
42
38
46
45
42
51
52
50
0.8
1.0
0.6
0.4
0.2
0.0
Overall survival
0
3
6
9
12
15
18
21
24
Time, months
Number at risk:
Lenvatinib/everolimus
Lenvatinib
Everolimus
15.4
months
25.5
months
27
48
50
46
10.1
months
extended median OS
Data cutoff: December 2014